Latest Non-alcoholic fatty liver disease Stories
According to the Centers for Disease Control and Prevention, 25 percent of Americans have inactive lifestyles (they take fewer than 5,000 steps a day) and 75 percent do not meet the weekly exercise recommendations (150 minutes of moderate activity each week and muscle-strengthening activity twice a week) to maintain good health.
New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV).
A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health.
Contradicting previous data, the use of vitamin E or the diabetes drug metformin, was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a new study.
In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents.
PARIS, April 22, 2011 /PRNewswire/ -- On the occasion of the 46th Congress of the European Association for the Study of the Liver, the VCTE(TM) (Vibration Controlled Transient Elastography) from Echosens stood out as a leading technique in the field.
Walking on a treadmill for one hour a day may slow the progression of nonalcoholic fatty liver disease in obese people with prediabetes by jump-starting their metabolism and slowing the oxidative damage wrought by the condition.
According to new data presented today at the International Liver CongressTM, the United States (U.S.) could soon be faced with an epidemic of Non-Alcoholic Fatty Liver Disease (NAFLD), one of the major contributing factors of chronic liver disease (CLD), considered as one of the major causes of morbidity and mortality worldwide.
OSAKA, Japan and NEW YORK, March 30, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc.
NEW YORK, March 29, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis (NASH), which will evaluate Intercept's first-in-class farnesoid X receptor (FXR) agonist obeticholic acid (OCA) as a novel therapy for NASH.